Hamilton, Ontario – October 19 – CPDC (Centre for Probe Development and Commercialization) today announced the appointment of Dr. John Valliant as Chair of its Board of Directors. Dr. Valliant succeeds Damian Lamb, who will continue to serve as a Director on the Board.
In 2008, while a professor at McMaster University, Dr. Valliant founded the CPDC, becoming its first Chief Executive Officer and making CPDC a driving force in the growth of the radiopharmaceutical sector in Canada and beyond. He also served as the founding Chief Executive Officer of Fusion Pharmaceuticals, leading the company from inception as a spin-out from CPDC and through its acquisition by AstraZeneca in 2024. Dr. Valliant also served on the Board of CPDC from 2008 through to 2024.
“I am honoured to rejoin the board of CPDC and assume the role of Chair and to work alongside the other Board members and the management team as CPDC continues to advance innovative radiopharmaceuticals to improve patient care,” said Dr. John Valliant, Chair of the Board, CPDC. “CPDC has played a unique role in building Canada’s radiopharmaceutical sector helping to ensure Canadians have access to new diagnostic and therapeutic technologies, and I look forward to helping guide its next phase of growth and impact.”
Damian Lamb, Co-founder and Managing Director of Genesys Capital, has served on the CPDC Board since its founding in 2008, including most recently as Chair. He will remain a Director on the Board.
“Having served on the CPDC Board since its founding, it has been a privilege to support the organization’s growth and mission,” said Damian Lamb, Director, CPDC. “John’s leadership at both CPDC and Fusion Pharmaceuticals makes him exceptionally well suited to lead the Board, and I look forward to continuing to work with him and the CPDC management team.”
Owen Roberts, Chief Executive Officer of CPDC, thanked Mr. Lamb for his leadership and welcomed Dr. Valliant to the role.
“On behalf of CPDC, I would like to thank Damian for his leadership and continuing commitment since CPDC’s founding in 2008,” said Owen Roberts, Chief Executive Officer, CPDC. “As a founding Board member and also as Chair, Damian has helped shape us into the organization we are today. With John’s experience as founding CEO of CPDC and his radiopharmaceutical expertise proven while leading Fusion Pharmaceuticals, he brings invaluable insight that will help us to continue to build and commercialize leading radiopharmaceutical innovations and grow the Canadian ecosystem.”
About CPDC
CPDC is a not-for-profit corporation founded in 2008, with the mission to improve the quality of Canadian patients’ lives through the commercialization of advanced research and the clinical development of nuclear medicine. In the past 18 years, CPDC has created four Canadian commercial entities that have advanced the availability of radiopharmaceuticals to the Canadian medical community. CPDC’s business model will continue to identify and advance critical radiopharmaceuticals to meet the needs of Canadian patients and physicians through commercialization and collaborations with its partners from industry, academia, and government.
For more information on CPDC visit www.cpdc.ca and follow on LinkedIn.
Contact:
Owen Roberts
CEO, CPDC
owen@cpdc.ca